Review Articles
Drugs in Focus
Domperidone
Maria Giovanna Puoti MD,
Amit Assa MD,
Marc Benninga MD, PhD,
Ilse Julia Broekaert MD,
Francisco Javier Martin Carpi MD,
Marco Deganello Saccomani MD, PhD,
Jernej Dolinsek MD,
Matjaz Homan MD,
Emmanuel Mas,
Erasmo Miele MD, PhD,
Christos Tzivinikos MD,
Mike Thomson MD,
Osvaldo Borrelli MD, PhD,
Maria Giovanna Puoti MD
Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK
Search for more papers by this authorAmit Assa MD
The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel
Search for more papers by this authorMarc Benninga MD, PhD
Department of Paediatric Gastroenterology and Nutrition, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
Search for more papers by this authorIlse Julia Broekaert MD
Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Search for more papers by this authorFrancisco Javier Martin Carpi MD
Department of Paediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain
Search for more papers by this authorMarco Deganello Saccomani MD, PhD
Department of Paediatrics, Woman’s & Child’s University Hospital of Verona, Verona, Italy
Search for more papers by this authorJernej Dolinsek MD
Department of Gastroenterology, Hepatology and Nutrition, University Medical Centre Maribor, Maribor, Slovenia
Search for more papers by this authorMatjaz Homan MD
Department of Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
Search for more papers by this authorEmmanuel Mas
Service de Gastroentérologie, Hépatologie, Nutrition, Diabétologie et Maladies Héréditaires du Métabolisme, Hôpital des Enfants, CHU de Toulouse, F-31300 Toulouse, France
IRSD, Université de Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France
Search for more papers by this authorErasmo Miele MD, PhD
Department of Translational Medicine Science, Section of Paediatrics, University of Naples “Federico II”, Naples, Italy
Search for more papers by this authorChristos Tzivinikos MD
Paediatric Gastroenterology Department, Al Jalila Children’s Specialty Hospital, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates
Search for more papers by this authorMike Thomson MD
Centre for Paediatric Gastroenterology, Sheffield Children’s Hospital, Weston Bank, Sheffield, UK
Search for more papers by this authorCorresponding Author
Osvaldo Borrelli MD, PhD
Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK
Address correspondence and reprint requests to Osvaldo Borrelli, MD, PhD, Department of Paediatric Gastroenterology, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3HZ, UK (e-mail: [email protected]).Search for more papers by this authorMaria Giovanna Puoti MD,
Amit Assa MD,
Marc Benninga MD, PhD,
Ilse Julia Broekaert MD,
Francisco Javier Martin Carpi MD,
Marco Deganello Saccomani MD, PhD,
Jernej Dolinsek MD,
Matjaz Homan MD,
Emmanuel Mas,
Erasmo Miele MD, PhD,
Christos Tzivinikos MD,
Mike Thomson MD,
Osvaldo Borrelli MD, PhD,
Maria Giovanna Puoti MD
Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK
Search for more papers by this authorAmit Assa MD
The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel
Search for more papers by this authorMarc Benninga MD, PhD
Department of Paediatric Gastroenterology and Nutrition, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
Search for more papers by this authorIlse Julia Broekaert MD
Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Search for more papers by this authorFrancisco Javier Martin Carpi MD
Department of Paediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain
Search for more papers by this authorMarco Deganello Saccomani MD, PhD
Department of Paediatrics, Woman’s & Child’s University Hospital of Verona, Verona, Italy
Search for more papers by this authorJernej Dolinsek MD
Department of Gastroenterology, Hepatology and Nutrition, University Medical Centre Maribor, Maribor, Slovenia
Search for more papers by this authorMatjaz Homan MD
Department of Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
Search for more papers by this authorEmmanuel Mas
Service de Gastroentérologie, Hépatologie, Nutrition, Diabétologie et Maladies Héréditaires du Métabolisme, Hôpital des Enfants, CHU de Toulouse, F-31300 Toulouse, France
IRSD, Université de Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France
Search for more papers by this authorErasmo Miele MD, PhD
Department of Translational Medicine Science, Section of Paediatrics, University of Naples “Federico II”, Naples, Italy
Search for more papers by this authorChristos Tzivinikos MD
Paediatric Gastroenterology Department, Al Jalila Children’s Specialty Hospital, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates
Search for more papers by this authorMike Thomson MD
Centre for Paediatric Gastroenterology, Sheffield Children’s Hospital, Weston Bank, Sheffield, UK
Search for more papers by this authorCorresponding Author
Osvaldo Borrelli MD, PhD
Department of Paediatric Gastroenterology, Great Ormond Street Hospital for Children, London, UK
Address correspondence and reprint requests to Osvaldo Borrelli, MD, PhD, Department of Paediatric Gastroenterology, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3HZ, UK (e-mail: [email protected]).Search for more papers by this authorThe authors report no conflicts of interest.
Abstract
Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted to relief of nausea and vomiting in children older than 12 years for a short period of time. However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (“off label”) for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis. Little is known about its efficacy in the treatment of GI motility disorders in children and controversial data have emerged in the pediatric literature. As its use is off label, appropriate knowledge of its efficacy is helpful to support an “off label/on evidence” prescription. Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.
REFERENCES
- 1.Barone J. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 1999; 33: 429–40.
- 2.Stern WR. Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. March 15 and 16, 1989 (omeprazole and domperidone). Am J Gastroenterol 1989; 84: 1351–5.
- 3. Medicines and Healthcare products Regulatory Agency. Domperidone: risks of cardiac side effects. Drug Safety Update. Available at: https://www.gov.uk/drug-safety-update/domperidone-risks-of-cardiac-side-effects. Published December 11, 2014. Accessed October 14, 2022.
- 4.Domperidone-containing medicines | European Medicines Agency (europa.eu). Available at: https://www.ema.europa.eu/en/medicines/human/referrals/domperidone-containing-medicines. Published September 2014. Accessed October 14, 2022.
- 5. How to Request Domperidone for Expanded Access Use. Available at: https://www.fda.gov/drugs/investigational-new-drug-ind-application/how-request-domperidone-expanded-access-use#:~:text=Physicians%20interested%20in%20submitting%20an,(above)%20to%20discuss%20domperidone. Published February 2, 2021. Accessed October 13, 2022.
- 6.Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979; 28: 2161–5.
- 7.Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJ. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 1986; 26: 628–32.
- 8.McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985; 80: 1008–16.
- 9.Meuldermans W, Hurkmans R, Swysen E, et al. On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981; 6: 49–60.
- 10.Michiels M, Hendriks R, Heykants J. On the pharmacokinetics of domperidone in animals and man. II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat. Eur J Drug Metab Pharmacokinet 1981; 6: 37–48.
- 11.Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012; 73: 411–21.
- 12.Hofmeyr GJ, Van Iddekinge B, Blott JA. Domperidone; secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol 1985; 92: 141–4.
- 13.da Silva OP, Knoppert DC. Domperidone for lactating women. CMAJ 2004; 171: 725–6.
- 14.Wan EW, Davey K, Page-Sharp M, Hartmann PE, Simmer K, Ilett KF. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol 2008; 66: 283–9.
- 15.Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6: 61–70.
- 16.https://www.medicines.org.uk/emc/product/556/smpc#gref. Published April 15, 2021. Accessed October 14, 2022.
- 17.Niemegeers CJ, Schellekens KH, Janssen PA. The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther 1980; 244: 130–40.
- 18.Takahashi T, Kurosawa S, Wiley JW, Owyang C. Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991; 101: 703–10.
- 19.Li ZS, Schmauss C, Cuenca A, Ratcliffe E, Gershon MD. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006; 26: 2798–807.
- 20.Weihrauch TR, Förster CF, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J 1979; 55: 7–10.
- 21.Bron B, Massih L. Domperidone: a drug with powerful action on the lower esophageal sphincter pressure. Digestion 1980; 20: 375–8.
- 22.Schulze-Delrieu K, Summers RW, Fink D. Domperidone in reflux esophagitis and gastric stasis. Lancet 1981; 1: 159.
- 23.Platteborse R, Hermans C, Loots W, et al. The effect of domperidone on pyloric activity in dog and in man. Postgrad Med J 1979; 55(suppl 1): 15–8.
- 24.Schuurkes JA, Van Nueten JM. Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites. Scand J Gastroenterol Suppl 1984; 96: 101–10.
- 25.Baeyens R, Van DeVelde E, DeSchepper A, et al. Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J 1979; 55(suppl 1): 19–23.
- 26.Wiley J, Owyang C. Dopaminergic modulation of rectosigmoid motility: action of domperidone. J Pharmacol Exp Ther 1987; 242: 548–51.
- 27.Lanfranchi GA, Marzio L, Cortini C, Osset EM. Motor effect of dopamine on human sigmoid colon: evidence for specific receptors. Dig Dis 1978; 23: 257–63.
- 28.Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ 1986; 135: 457–61.
- 29.Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics 2006; 117: 1887–92.
- 30.Ogilvie I, Khoury H, Goetghebeur MM, El Khoury AC, Giaquinto C. Burden of community acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis 2012; 12: 62.
- 31.Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–52.
- 32.King CK, Glass R, Bresee JS, Duggan C; Centers for Disease Control and Prevention. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52: 1–16.
- 33.Khanna R, Lakhanpaul M, Burman-Roy S, Murphy MS; Guideline Development Group and the technical Team. Diarrhoea and vomiting caused by gastroenteritis in children under 5 years: summary of NICE guidance. BMJ 2009; 338: b1350.
- 34.Rerksuppaphol S, Rerksuppaphol L. Randomized study of ondansetron versus domperidone in the treatment of children with acute gastroenteritis. J Clin Med Res 2013; 5: 460–6.
- 35.Hanif H, Jaffry H, Jamshed F, et al. Oral ondansetron versus domperidone for acute gastroenteritis associated vomiting in young children. Cureus 2019; 11: e5639.
- 36.Salma-Kamal SK, Kudagi BL, Bathina P, et al. Clinical outcome with single dose ondansetron versus domperidone in paediatric gastroenteritis-our experience. J Med Sci Clin Res 2015; 3: 6273–7.
- 37.Marchetti F, Bonati M, Maestro A, et al. Oral ondansetron versus domperidone for acute gastroenteritis in pediatric emergency departments: multicenter double blind randomized controlled trial. PLoS One 2016; 11: e0165441.
- 38.Leitz G, Hu P, Appiani C, et al. Safety and efficacy of low-dose domperidone for treating nausea and vomiting due to acute gastroenteritis in children. J Pediatr Gastroenterol Nutr 2019; 69: 425–30.
- 39.Kita F, Hinotsu S, Yorifuji T, et al. Domperidone with ORT in the treatment of pediatric acute gastroenteritis in Japan: a multicenter, randomized controlled trial. Asia Pac J Public Health 2015; 27: NP174–83.
- 40.Niño-Serna LF, Acosta-Reyes J, Veroniki AA, Florez ID. Antiemetics in children with acute gastroenteritis: a meta-analysis. Pediatrics 2020; 145: e20193260.
- 41.Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35: 119–36.
- 42.Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360–400.
- 43.Zamani NF, Sjahid AS, Kamauzaman THT, Lee YY, Islam MA. Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials. J Clin Med 2022; 11: 5268.
- 44.Manzotti ME, Catalano HN, Serrano FA, Di Stilio G, Koch MF, Guyatt G. Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials. Open Med 2007; 1: e171–80.
- 45.Isshi K, Furuhashi H, Nakada K. Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia. JGH Open 2020; 4: 582–8.
- 46.Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014; 20: 2412–9.
- 47.Clara R. Chronic regurgitation and vomiting treated with domperidone. A multicenter evaluation. Acta Paediatr Belg 1979; 32: 203–7.
- 48.De Loore I, Van Ravensteyn H, Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgrad Med J 1979; 55(suppl 1): 40–2.
- 49.Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M, Notarbartolo A. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo. Scand J Gastroenterol 1994; 29: 300–4.
- 50.Bines JE, Quinlan JE, Treves S, Kleinman RE, Winter HS. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400–5.
- 51.Grill BB, Hillemeier A, Semeraro LA, McCallum RW, Gryboski JD. Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux. J Pediatr 1985; 106: 311–6. doi:10.1016/s0022-3476(85)80315-2.
- 52.Hegar B, Alatas S, Advani N, Firmansyah A, Vandenplas Y. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. Acta Paediatr 2009; 98: 750–5.
- 53.Cresi F, Marinaccio C, Russo MC, Miniero R, Silvestro L. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. J Perinatol 2008; 28: 766–70.
- 54.Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev 2014; 2014: CD008550.
- 55.Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66: 516–54.
- 56. Gastro-esophageal reflux disease in children and young people: diagnosis and management. NICE guidelines. 2014. Available at: https://www.nice.org.uk/guidance/ng1. Published January 14, 2015. Accessed November 1, 2022.
- 57.Camilleri M, Parkman H, Shafi M, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: 18–37.
- 58.Vijayvargiya P, Camilleri M, Chedid V, Mandawat A, Erwin PJ, Murad MH. Effects of promotility agents on gastric emptying and symptoms: a systematic review and meta-analysis. Gastroenterology 2019; 156: 1650–60.
- 59.Jacobs F, Akkermans LMA, Yol OH, Wittebol P. Effects of domperidone on gastric emptying of semi-solid and solid food. Progress with Domperidone. R Soc Med Int Congr Symp Ser 1981; 36: II–19.
- 60.Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230–4.
- 61.Sarosiek I, Van N, Parkman HP, et al. Effect of domperidone therapy on gastroparesis symptoms: results of a dynamic cohort study by NIDDK Gastroparesis Consortium. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium (GpCRC). Clin Gastroenterol Hepatol 2022; 20: e452–64.
- 62.Ingrosso MR, Camilleri M, Tack J, et al. Efficacy and safety of drugs for gastroparesis review and network meta-analysis. Gastroenterology 2023; 164(4): 642–54.
- 63.Rodriguez L, Irani K, Jiang H, Goldstein AM. Clinical presentation, response to therapy, and outcome of gastroparesis in children. J Pediatr Gastroenterol Nutr 2012; 55: 185–90.
- 64.Franzese A, Borrelli O, Corrado G, et al. Domperidone is more effective than cisapride in children with diabetic gastroparesis. Aliment Pharmacol Ther 2002; 16: 951–7.
- 65.Gounaris A, Costalos C, Varchalama E, et al. Gastric emptying of preterm neonates receiving domperidone. Neonatology 2010; 97: 56–60.
- 66.Sukwuttichai P, Boonkasidecha S, Montakantikul P, Vimolsarawong N. Efficacy comparison between oral erythromycin versus domperidone for the treatment of feeding intolerance in preterm neonates. Pediatr Neonatol 2021; 62: 543–9.
- 67.Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology 2016; 150: 12.
- 68.Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016; 150: 1380–92.
- 69.Arts E, Anthoni H, de Roy G, D'Hollander J, Verhaegen H. Domperidone in the treatment of dyspepsia: a double-blind placebo-controlled study. J Int Med Res 1979; 7: 158–61.
- 70.Milo R. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980; 6: 577–84.
- 71.Englert W, Schlich D. A double-blind crossover trial of domperidone in chronic postprandial dyspepsia. Postgrad Med J 1979; 55(suppl 1): 28–9.
- 72.Haarmann K, Lebkuchner F, Widmann A, Kief W, Esslinger M. A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress. Postgrad Med J 1979; 55(suppl 1): 24–7.
- 73.Van de Mierop L, Rutgeerts L, Van den Langenbergh B, Staessen A. Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation. Digestion 1979; 19: 244–50.
- 74.Sander JO, Veldhuyzen van Zanten SJ, Michael JJ, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689–96.
- 75.Liang L, Yu J, Xiao L, Wang G. Comparative efficacy of various pharmacological interventions in the treatment of functional dyspepsia: a network meta-analysis. Dig Dis Sci 2022; 67: 187–207.
- 76.Karunanayake A, Devanarayana NM, de Silva A, Gunawardena S, Rajindrajith S. Randomized controlled clinical trial on value of domperidone in functional abdominal pain in children. J Pediatr Gastroenterol Nutr 2018; 66: 725–31.
- 77.Dehghani SM, Askarian M, Kaffashan HA. Oral domperidone has no additional effect on chronic functional constipation in children: a randomized clinical trial. Indian J Gastroenterol 2014; 33: 125–30.
- 78.Lanfranchi GA, Bazzocchi G, Fois F, et al. Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1985; 29(3): 307–10.
- 79.Cann PA, Read NW, Holdsworth CD. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. Gut 1983; 12: 1135–40.
10.1136/gut.24.12.1135 Google Scholar
- 80.Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984; 2: 1336–7.
- 81.Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet 1982; 1: 1019.
- 82.Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1984; 289: 1579.
- 83.Arana A, Johannes CB, McQuay LJ, Varas-Lorenzo C, Fife D, Rothman KJ. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study. Drug Saf 2015; 38: 1187–99.
- 84.van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MCJM. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010; 33: 1003–14.
- 85.Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883–5.
- 86.Chen HL, Hsiao FY. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study. Pharmacoepidemiol Drug Saf 2015; 24: 841–8.
- 87.Bor S, Demir M, Ozdemir O, Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J 2018; 6: 1331–46.
- 88.Günlemez A, Babaoğlu A, Arisoy AE, Türker G, Gökalp AS. Effect of domperidone on the QTc interval in premature infants. J Perinatol 2010; 30: 50–3.
- 89.Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153: 663–6. doi:10.1016/j.jpeds.2008.05.013.
- 90.Rocha CMG, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720–3.
- 91.Ngoenmak T, Treepongkaruna S, Buddharaksa Y, Khositseth A. Effects of domperidone on QT interval in children with gastroesophageal reflux disease. Pediatr Neonatol 2016; 57: 60–4.
- 92.Vieira MC, Miyague NI, Van Steen K, Salvatore S, Vandenplas Y. Effects of domperidone on QTc interval in infants. Acta Paediatr 2012; 101: 494–6.
- 93.Morris AD, Chen J, Lau E, Poh J. Domperidone-associated QT interval prolongation in non-oncologic pediatric patients: a review of the literature. Can J Hosp Pharm 2016; 69: 224–30.
- 94.Tang KL, Mokhti FA, Fong JY, et al. Domperidone-related acute dystonia in a young child with underlying abnormal electroencephalogram. Int J Clin Pediatr 2020; 9: 55–8.
10.14740/ijcp364 Google Scholar
- 95.Shahbaz A, Elahi K, Affan M, Shahid MF, Sabir A. Acute dystonia secondary to domperidone in a pediatric patient. Cureus 2018; 10: e3587.
- 96.Dhakal OP, Dhakal M, Bhandari D. Domperidone-induced dystonia: a rare and troublesome complication. BMJ Case Rep 2014; 2014:bcr2013200282.
10.1136/bcr-2013-200282 Google Scholar
- 97.Roy-Desruisseaux J, Landry J, Bocti C, Tessier D, Hottin P, Trudel J-F. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011; 45: e51.
- 98.Daripa B, Lucchese S. A rare case of domperidone-induced acute dystonia in a young adult due to consumption of combination drug (proton pump inhibitors with domperidone) and its possible pathomechanism. Cureus 2022; 14: e23723.
- 99.Thuan ND, Nhung VP, Dung HT, Son ND, Hai Ha N, Ton ND. Acute extrapyramidal side effects following domperidone intake in a 48-year-old female patient: the first genetic alteration and drug interaction characterized. J Mov Disord 2022; 15: 193–5.
Citing Literature
